Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 105 Records) |
Query Trace: Diarrhea and UGT1A1[original query] |
---|
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2017 02 37 (1): 35-42. Deng Bo, Jia Liqun, Tan Huangying, Lou Yanni, Li Xue, Li Yuan, Yu Li |
UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan. Cancer science 2018 Sep . Kimura Kei, Yamano Tomoki, Igeta Masataka, Imada Ayako, Jihyung Song, Babaya Akihito, Hamanaka Michiko, Kobayashi Masayoshi, Tsukamoto Kiyoshi, Noda Masafumi, Ikeda Masataka, Tomita Naohi |
Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer. Integrative cancer therapies 2018 9 17 (4): 1109-1114. Lu Hongyang, Qin Jing, Han Na, Xie Fajun, Gong Lei, Li Chengh |
[Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2018 Aug 40 (8): 594-599. Wang X F, Ma C, Gong F F, Yi S Y, Xing G C, Wang K J, Yang Q, Cao |
Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. Tumori 2018 12 106 (2): 87-94. Paulík Adam, Nekvindová Jana, Filip Stanisl |
Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer science 2019 Feb 110 (2): 707-716. Shirasu Hiromichi, Todaka Akiko, Omae Katsuhiro, Fujii Hirofumi, Mizuno Nobumasa, Ozaka Masato, Ueno Hideki, Kobayashi Satoshi, Uesugi Kazuhiro, Kobayashi Noritoshi, Hayashi Hideyuki, Sudo Kentaro, Okano Naohiro, Horita Yosuke, Kamei Keiko, Yukisawa Seigo, Kobayashi Marina, Fukutomi Aki |
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer chemotherapy and pharmacology 2019 Jan 83 (1): 123-129. Fujii Hironori, Yamada Yunami, Watanabe Daichi, Matsuhashi Nobuhisa, Takahashi Takao, Yoshida Kazuhiro, Suzuki Ak |
A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. Cancer chemotherapy and pharmacology 2018 10 82 (6): 1021-1029. Hamaguchi Tetsuya, Tsuji Akihito, Yamaguchi Kensei, Takeda Koji, Uetake Hiroyuki, Esaki Taito, Amagai Kenji, Sakai Daisuke, Baba Hideo, Kimura Masami, Matsumura Yasuhiro, Tsukamoto Tetsu |
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 9 26 (1): 18-24. Joshi Smita S, Catenacci Daniel V T, Karrison Theodore G, Peterson Jaclyn D, Zalupski Mark M, Sehdev Amikar, Wade James, Sadiq Ahad, Picozzi Vincent J, Amico Andrea, Marsh Robert, Kozloff Mark F, Polite Blase N, Kindler Hedy L, Sharma Manish |
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Therapeutic advances in medical oncology 2019 6 11 1758835919846421. Bruera Gemma, Massacese Silvia, Pepe Francesco, Malapelle Umberto, Dal Mas Antonella, Ciacco Eugenio, Calvisi Giuseppe, Troncone Giancarlo, Simmaco Maurizio, Ricevuto Enri |
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2019 1 22 (4): 778-784. Yamaguchi Toshifumi, Iwasa Satoru, Shoji Hirokazu, Honma Yoshitaka, Takashima Atsuo, Kato Ken, Hamaguchi Tetsuya, Higuchi Kazuhide, Boku Narika |
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer 2019 Jan . Sharma Manish R, Joshi Smita S, Karrison Theodore G, Allen Kenisha, Suh Grace, Marsh Robert, Kozloff Mark F, Polite Blase N, Catenacci Daniel V T, Kindler Hedy |
Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis. Bioscience reports 2020 Sep . Zhu Xiaoyun, Ma Ruchao, Ma Xin, Yang Ga |
ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in pharmacology 2020 7 11 973. Riera Pau, Artigas-Baleri Alícia, Salazar Juliana, Sebio Ana, Virgili Anna C, Arranz María Jesús, Páez Dav |
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang. BMC gastroenterology 2020 Apr 20 (1): 96. Chen Shaojun, Hua Li, Feng Chengjun, Mo Qia, Wei Mengzhuan, Shen Yongqi, Lin Zhan, Li Guisheng, Xu Junyi, Guo Chengxian, Huang Haix |
Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 10 38 (36): 4231-4239. Zhu Ji, Liu Anwen, Sun Xinchen, Liu Luying, Zhu Yaqun, Zhang Tao, Jia Jianhui, Tan Shisheng, Wu Junxin, Wang Xin, Zhou Juying, Yang Jialin, Zhang Chen, Zhang Hongyan, Zhao Yuanyuan, Cai Gang, Zhang Wei, Xia Fan, Wan Juefeng, Zhang Hui, Shen Lijun, Cai SanJun, Zhang Zh |
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021 4 13 (7): . Nelson Ryan S, Seligson Nathan D, Bottiglieri Sal, Carballido Estrella, Cueto Alex Del, Imanirad Iman, Levine Richard, Parker Alexander S, Swain Sandra M, Tillman Emma M, Hicks J Kev |
Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen. Pharmacogenomics and personalized medicine 2021 14 369-377. Zhu Xiaoqin, Zhu Jia, Sun Feifei, Zhen Zijun, Zhou Dalei, Lu Suying, Huang Junting, Que Yi, Zhang Lian, Cai Ruiqing, Wang Juan, Zhang Yizh |
UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival. The oncologist 2021 Mar . Bandyopadhyay Ankan, Sharma Siddharth, Behera Digambar, Singh Navne |
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT: pharmacometrics & systems pharmacology 2021 11 10 (12): 1550-1563. Brendel Karl, Bekaii-Saab Tanios, Boland Patrick M, Dayyani Farshid, Dean Andrew, Macarulla Teresa, Maxwell Fiona, Mody Kabir, Pedret-Dunn Anna, Wainberg Zev A, Zhang B |
[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2021 11 43 (11): 1177-1182. Wang X, Liu Y, Huang J X, Lu P, Ba Y, Wu L, Bai Y X, Zhang S, Feng J F, Cheng Y, Li J, Wen L, Yuan X L, Ma C W, Hu C H, Fan Q X, Xu B H, Huang |
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 2022 Aug 8 (1): 98. Rugo Hope S, Tolaney Sara M, Loirat Delphine, Punie Kevin, Bardia Aditya, Hurvitz Sara A, O'Shaughnessy Joyce, Cortés Javier, Diéras Véronique, Carey Lisa A, Gianni Luca, Piccart Martine J, Loibl Sibylle, Goldenberg David M, Hong Quan, Olivo Martin, Itri Loretta M, Kalinsky Kev |
Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clinical and translational science 2022 May . Atasilp Chalirmporn, Biswas Mohitosh, Jinda Pimonpan, Nuntharadthanaphong Nutthan, Rachanakul Jiratha, Hongkaew Yaowaluck, Vanwong Natchaya, Saokaew Surasak, Sukasem Chonlaph |
Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2022 3 25 (3): 137-146. Li Qian, Sun Tao, Zhang Hua, Liu Wei, Xiao Yu, Sun Hongqi, Yin Wencheng, Yao Yanhong, Gu Yangchun, Liu Yan'e, Yi Fumei, Wang Qiqi, Yu Jinyu, Cao Baoshan, Liang |
Delayed Diagnosis of Clostridium difficile Colitis in a 48-Year-Old Woman with a Homozygous Mutation of the UGT1A1 Gene While on Chemotherapy for Colorectal Carcinoma. The American journal of case reports 2022 2 23 e934361. Caramoci Adela, Grigorescu Alexandru, Pop Mirela, Ionescu Anca Mire |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. ESMO open 2022 12 8 (1): 100746. Su Y-Y, Chiang N-J, Chang J S, Wang Y-W, Shen B-N, Li Y-J, Hwang D-Y, Shan Y-S, Chen L |
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & informatics 2022 Sep 20 (3): e29. Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You |
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: